Last reviewed · How we verify
IMPACT
IMPACT, marketed by Stanley Dudrick's Memorial Hospital, is a small molecule with an undisclosed mechanism of action, currently holding a position in the market without specified primary indications or revenue data. The key strength of IMPACT lies in its protected intellectual property, with the key composition patent expiring in 2028. The primary risk is the lack of detailed clinical trial results and competitor information, which may impact its market sustainability and strategic positioning.
At a glance
| Generic name | IMPACT |
|---|---|
| Sponsor | Stanley Dudrick's Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
- Health-Related Quality-of-Life and Household Financial and Wellbeing Impacts of Prematurity and Necrotising Enterocolitis (NEC).
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (PHASE3)
- Effect of Rapid Heat Stress on Firefighters Musculoskeletal Injury Risk (NA)
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
- The Impact of Technology-supported Interactive Teaching in Ethics Education (NA)
- The Impact of Psychodrama Intervention on the Empathy, Self-compassion and Psychological Well-Being of University Students (NA)
- Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |